Excerpt
Described by physicians during the clinical trials as a "quantum leap forward" the Bx VELOCITY is indicated for use in patients for whom previous interventional therapy failed. The stent is approved to treat lesions 30 mm in length and smaller with reference diameters in the range of 2.25 mm to 4.00 mm.
The Bx VELOCITY stent is available in diameters ranging from 2.25 mm to 3.0 mm in quarter-size increments and from 3.5 mm to 4.0 mm in half-size increments. Lengths include 8 mm, 13 mm, 18 mm, 23 mm, 28 mm, and 33 mm. Unlike any other stent, the Bx VELOCITY is cut from three distinct tube sizes designed for specific diameter ranges.
FIGURE The Bx VELOCITY stent delivery system features 16-atm (atmospheres) rated burst pressure capability and has only 1 mm of balloon overhang at the stent margins. To reduce the risk of edge dissection, the delivery system utilizes Cordis' new RAPTOR™ balloon technology, which will not expand beyond the outside edge of the stent-a phenomenon commonly referred to as "dog-boning." The delivery system also has a very low profile, which reduces friction and allows smooth transitions around bends, through calcium, and through previously deployed stents.
The compliance of TALON™ balloon material featured on the RAPTOR stent delivery system is optimally matched to clinical needs-being less compliant in smaller diameters.
For more information on the Bx VELOCITY stent, visit the "product showcase" at www.cordis.com.
Cordis Cardiology is a unit of Cordis Corporation, a broad-based supplier of products for circulatory disease management. Established in 1959, Cordis Corporation is the world's largest, most comprehensive developer and manufacturer of innovative products for interventional medicine, minimally invasive computer-based imaging, and electrophysiology. In 1996, Cordis Corporation merged with Johnson & Johnson to form Cordis, a Johnson & Johnson company, with approximately 3,500 employees worldwide.